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SUMMARY  
 
Seventy-eight consecutive patients with Stage IIB osteosarcoma of the appendicular 
skeleton, treated between 1982 and 1992, were studied to determine whether the 
technique of biopsy affected the prognosis for long term survival. The risk of local 
recurrence was significant (p < 0.02) after opera biopsy, as was the poor response to 
chemotherapy (p < 0.05) after percutaneous biopsy. We recommend percutaneous 
biopsy, if possible, when an osteosarcoma is suspected. 
 
 
RÉSUMÉ 
 
Étude de 78 malades atteints d'ostéosarcome des membres de stade II-B, traités de 1982 
à 1991. Le but de ce travail est de savoir si le type de biopsie réalisé a une influence sur 
le pronostic vital. Le risque de récidive locale est significativement plus élevé (p < 0.02) 
en cas de biopsie ouverte. Une mauvaise réponse à la chimiothérapie est plus fréquente 
(p < 0.05) en cas de biopsie per-cutanée. Néanmoins, en cas de soupçon d'ostéo-
sarcome, nous conseillons de réaliser; chaque fois que possible, une biopsie percutanée. 
 
 
INTRODUCTION 
 
Many reports attempt to identify the factors which may affect the prognosis in 
osteosarcoma [2, 4, 7, 11, 12, 13, 16, 18, 20, 23, 25, 26, 31, 35, 38]. 
 
We wanted to estimate the long term prognosis in a series of patients with osteosarcoma 
receiving adjuvant chemotherapy in a single institution, and to determine whether the 
technique of biopsy was a prognostic factor in the long term survival, and also to 
estimate the magnitude of the effect of this factor on survival. 
 
 
MATERIALS AND METHODS  
 
The records of all the 128 patients who presented at our hospital with the diagnosis of 
osteosarcoma between 1982 and 1992 were reviewed. The current series was restricted 
to patients with primary high grade nonmetastatic osteogenic sarcoma of the 
appendicular skeleton who had their definitive surgical treatment in the Department of 
Orthopaedic Surgery. Exclusions are shown in Table 1. 
 
The follow up ranged from 12 to 156 months (median 48.9 months). The combined 
population experience of this study included more than 350 patient-years of 
observation. Every patient was included in a chemotherapy protocol [36]. 
The patients were treated either by amputation or limb-sparing surgery. Selection was 
based on the site of the primary tumour or neurovascular involvement. 
 
 
Statistical analysis  
 
Time zero in all analyses was taken as the date of definitive diagnosis by biopsy. The 
univariate survival analysis was performed following the Kaplan-Meier product-limit 
estimate [21]. One patient, who was free of disease, died of complications related to 
treatment while receiving postoperative chemotherapy and was excluded from the 
study. We have used a Macintosh Classic and StatviewTM programme. 
 
 
RESULTS 
 
Eighty-six patients were within the inclusion criteria. Of these, 8 (9.3%) had metastatic 
disease (stage III). The remaining 78 had localised disease and received comprehensive 
treatment in our hospital; they comprise the case series in this study. 
 
There were 38 boys and men with a mean age of 18 ± 8 years (range 5 to 45 years), and 
44 girls and women with a mean age of 16 ± 6 years, (range 4 to 40 years) (Fig. 1). The 
sites of the lesions are shown in Table 2. 
 
The definitive surgery was amputation in 2 patients (2.6%) and limb-sparing excision in 
76 (97.4%). Table 3 describes the treatment according to the site of the lesion. The 
margins of surgery, as defined by the Musculoskeletal Tumour Society [9], were wide 
in 38 patients (49.9%), radical in 2 (2.6%), marginal in 33 (42.9%) and intralesional in 5 
(6.5%). 
 
Percutaneous biopsy was carried out in 25 patients and open biopsy in 52; these 
procedures were all undertaken in other hospitals. 
 
 
Survival 
 
Data from all the patients was analysed. Of the 78 observed, 12 died from local 
recurrence, 11 from metastases and one from toxicity. 
 
Out of all the patients, 10 (12.8%) had a local recurrence and 17 (21.8%) had 
metastases. The site of the metastasis was lung in 16 cases, and bone in one case. Seven 
patients had both lung metastases and local recurrence. 
 
The disease-free survival was 74.36% at 5 years and 70.27% at 10 years (Kaplan-Meier) 
(Fig. 2). All those with local recurrence (10 cases) had had an open biopsy (p < 0.02). 
The response to chemotherapy was better in the those with an open biopsy (p < 0.05) 
(Table 4). 
 
 
 
 
DISCUSSION 
 
We have identified that the technique used in biopsy is a factor that could predict the 
outcome in patients with osteosarcoma. The characteristics of our patients were similar 
to those in other series [8, 12, 27, 37], as were our survival rates [8, 12, 14, 20, 27] 
Table 5. No difference was found between the disease-free survival in patients treated 
by amputation or limb salvage [6, 12, 14, 24, 33]. 
 
Local recurrence after treatment of osteosarcoma carries a very bad prognosis. The 
incidence of local recurrence has been reported as 12% [17] and 16.1% [40], compared 
with 12.8% in our series. 
 
We have found significant differences in local recurrence after biopsy, and all 
recurrences have followed an open technique. We do not know why open biopsy had a 
better chemotherapeutic response than percutaneous biopsy. An open biopsy can injure 
the circulation around the tumour. 
 
We therefore propose that percutaneous biopsy under radiographic control should be 
carried out when osteosarcoma is suspected, and this is the policy of other surgeons [3, 
5, 10, 16, 19, 28, 30, 34]. We only advise open biopsy when the result of percutaneous 
biopsy is not conclusive. Open biopsy should be performed carefully, bearing in mind 
the definitive surgery which may be necessary when planning the approach. 
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Table 1. The cases excluded from the group studied 
Primary surgical treatment elsewhere 6 
Axial site 10 
Lesion secondary to Paget's disease or radiation 1 
Metastatic disease on presentation 8 
Refused our treatment 25 
Total excluded 49 
Total in the current series 78 
 
 
Table 2. The skeletal site of the tumours 
Upper limb  5 
Humerus Proximal 0 
 Middle 1 
 Distal 1 
Radius   
Lower limb   
Femur Proximal 3 
 Middle 6 
 Distal 37 
Tibia Proximal 17 
 Middle 2 
 Distal 3 
Fibula  2 
Calcaneus  1 
Total  78 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Brief details of the surgical treatment 
 Humerus Radius Femur Tibia Fibula 
 Proximal Distal  Proximal Middle Distal Proximal Middle Distal  
Allografts ― ― ― ― ― ― ― ― ― ― 
Knee prostheses ― ― ― ― ― 17 9 ― ― ― 
Hip prostheses ― ― ― 1 1 ― ― ― ― ― 
Osteoarticular 1 1 ― ― ― 1 ― ― 1 ― 
Intercalary ― ― ― ― 5 8 3 1 ― ― 
Arthrodesis ― ― ― ― ― 3 ― ― 2 ― 
Autografts ― ― ― ― ― ― ― ― ― ― 
Intercalary ― ― 1 ― ― 3 ― 1 ― ― 
Endoprostheses ― ― ― ― ― ― ― ― ― ― 
Knee ― ― ― ― ― 4 4 ― ― ― 
Hip ― ― ― 2 ― ― ― ― ― ― 
Shoulder 4 ― ― ― ― ― ― ― ― ― 
Resection ― ― ― ― ― ― ― ― ― 2 
Bone transplant ― ― ― ― ― 1 ― ― ― ― 
 
 
 
Table 4. Response to chemotherapy 
 Poor response (%) Good response (%) 
Biopsy type:   
Open 12 (29) 30 (71) 
Percutaneous 9 (45) 10 (55) p < 0,05 
 
 
 
Table 5. Disease-free survival – comparison with other series 
Centre 
Survival     
5 years 
10 years 
Rizzoli (Bologna) [1] 82% (3 years) 
Sloan-Kettering Memorial (New York) [12] 77% 74% 
University Clinic of Vienna [22] 76% (3 years) 
AC Camargo Hospital (Sao Paulo) [31] 61% (3 years) 
MD Anderson (Houston) [14] 58% 58% 
All-union Cancer Research Center (Moscow) [39] 58%  
Royal Prince Alfred Hospital (Sydney) [29] 58%  
Royal Orthopaedic Hospital (Birmingham) [6] 48%  
  
 
 
 
 
 
 
 
 Figure 1. Age and gender of the patients 
 
 
 
 
 
 
 Figure 2. Disease-free survival (Kaplan-Meier) 
